Bile acids acting as inflammation regulators may protect against IBD
Research has found that bile acids, converted by gut microbes, act as inflammatory regulators in IBD by modulating the differentiation of T cells in the gut.
List view / Grid view
Research has found that bile acids, converted by gut microbes, act as inflammatory regulators in IBD by modulating the differentiation of T cells in the gut.
Drug Target Review lists its 10 most popular news stories from 2019, summarising the drug targets that you wanted to read about.
A study has found a new molecular process in mice that causes autoimmune diseases and has opened avenues for developing more effective autoimmune therapies.
Researchers have found that a type of T cell, called a Tr1 cell, could work as a therapeutic strategy for inflammatory bowel disease in children.
Researchers have reported finding on an epigenetic signature in patient cells that appears to predict inflammation risk in Crohn's disease...
Researchers propose a novel approach to manipulate genes that may hold the key to the future of personalised medicine...
A stem cell-derived in vitro model displays key small intestine characteristics including innate immune responses.
By surveying gene expression, researchers have created a reference atlas for understanding the biology of inflammatory bowel disease and food allergies, among other conditions...
Researchers have used a modified version of the gene-editing technique CRISPR in search for gene activators...
20 June 2016 | By Victoria White, Digital Content Producer
The funding, led by Epidarex Capital, will support the Mironid’s internal research and preclinical development programmes...
17 June 2016 | By Victoria White, Digital Content Producer
Researchers have identified interactions between immune system pathways which could improve the treatment of diseases such as inflammatory bowel disease...
19 April 2016 | By Victoria White, Digital Content Producer
Enterome has signed a license agreement with Vertex to research, develop and commercialise novel small molecule FimH antagonists...
15 July 2015 | By Victoria White
Galapagos has entered into a licensing agreement with the HUB foundation for use of Organoid Technology for preclinical research in cystic fibrosis and IBD...